Sivik Global Healthcare LLC Takes $4.48 Million Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Sivik Global Healthcare LLC purchased a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 40,000 shares of the biopharmaceutical company's stock, valued at approximately $4,482,000. Gilead Sciences makes up 2.4% of Sivik Global Healthcare LLC's portfolio, making the stock its 22nd largest position.

A number of other hedge funds have also added to or reduced their stakes in the company. Norges Bank bought a new position in Gilead Sciences in the fourth quarter valued at about $1,789,254,000. FMR LLC boosted its stake in shares of Gilead Sciences by 21.6% in the 4th quarter. FMR LLC now owns 40,319,432 shares of the biopharmaceutical company's stock valued at $3,724,306,000 after purchasing an additional 7,157,113 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Gilead Sciences by 13,891.1% during the 1st quarter. GAMMA Investing LLC now owns 2,550,298 shares of the biopharmaceutical company's stock valued at $285,761,000 after purchasing an additional 2,532,070 shares during the last quarter. Northern Trust Corp increased its position in Gilead Sciences by 19.7% during the 4th quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after purchasing an additional 2,458,954 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in Gilead Sciences in the 4th quarter valued at approximately $207,340,000. 83.67% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total value of $3,010,560.00. Following the sale, the insider now owns 121,152 shares of the company's stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, May 30th. The stock was sold at an average price of $110.42, for a total transaction of $1,104,200.00. Following the completion of the sale, the chief executive officer now directly owns 620,268 shares in the company, valued at $68,489,992.56. This trade represents a 1.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,500 shares of company stock valued at $5,236,245. Insiders own 0.27% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have weighed in on GILD shares. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the stock an "overweight" rating in a research note on Thursday, March 27th. Wells Fargo & Company raised their price objective on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Oppenheimer lowered their target price on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Bank of America increased their target price on Gilead Sciences from $116.00 to $126.00 and gave the company a "buy" rating in a research report on Wednesday, March 5th. Finally, Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $110.55.

Gilead Sciences Stock Down 2.1%

NASDAQ:GILD traded down $2.31 on Monday, hitting $106.19. The stock had a trading volume of 8,170,901 shares, compared to its average volume of 7,663,618. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. Gilead Sciences, Inc. has a 52 week low of $66.01 and a 52 week high of $119.96. The business's fifty day moving average is $106.16 and its 200 day moving average is $102.88. The company has a market cap of $132.09 billion, a PE ratio of 22.36, a P/E/G ratio of 0.70 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm's revenue for the quarter was down .3% compared to the same quarter last year. During the same quarter last year, the firm earned ($1.32) EPS. On average, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 27th. Investors of record on Friday, June 13th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 2.98%. The ex-dividend date is Friday, June 13th. Gilead Sciences's payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.